MESOBLAST LTD

Develops off-the-shelf cellular medicines for complex inflammatory and chronic diseases.

MESO | NDAQ

Overview

Corporate Details

ISIN(s):: US5907171046 (+1 more)
LEI:
Country:: United States of America
Address:: LEVEL 38, 3000 MELBOURNE, VICTORIA
Website:: https://www.mesoblast.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Mesoblast is a regenerative medicine company focused on developing and commercializing allogeneic (off-the-shelf) cellular medicines. The company utilizes its proprietary mesenchymal lineage cell technology platform to create innovative treatments for complex inflammatory diseases and other conditions resistant to conventional therapies. Its platform is based on cells collected from healthy adult donors, which are expanded at an industrial scale. A key feature of its product candidates is the ability to be administered without donor-recipient matching or recipient immune suppression. Mesoblast's advanced portfolio includes Phase 3 product candidates targeting steroid-refractory acute graft versus host disease (GVHD), acute respiratory distress syndrome (ARDS), advanced chronic heart failure, and chronic low back pain.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all MESOBLAST LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MESOBLAST LTD

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for MESOBLAST LTD via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
ANTEROGEN CO., LTD. Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.	South Korea	065660
Antibiotice S.A. Develops and manufactures generic medicines and APIs, specializing in anti-infectives.	Romania	ATB
Apellis Pharmaceuticals, Inc. Developing novel C3 therapies for diseases in ophthalmology, nephrology, and hematology.	United States of America	APLS
Apimeds Pharmaceuticals US, Inc. Biopharma developing non-narcotic bee venom therapies for osteoarthritis pain and inflammation.	United States of America	APUS
Apogee Therapeutics, Inc. Developing novel antibody biologics for immunological and inflammatory (I&I) diseases.	United States of America	APGE
Apollomics Inc. A clinical-stage biopharma developing targeted oncology therapies for hard-to-treat cancers.	United States of America	APLM
Apontis Pharma AG German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.	Germany	APPH
APPLIED DNA SCIENCES INC Develops DNA tech for genetic medicine, molecular diagnostics, and supply chain security.	United States of America	APDN
Applied Therapeutics, Inc. Develops treatments for rare metabolic and central nervous system (CNS) disorders.	United States of America	APLT
Aprea Therapeutics, Inc. Developing precision cancer therapies targeting DNA Damage Response for solid tumors.	United States of America	APRE